600 patients66,869 observations120 daysLIVE

Patient P-01877

Synthetic patientNBL-101 · Day 118 · 35–44 · M · baseline S01Open companion preview
Therapy response
Favorable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
89%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S01
  2. Day 79 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 82 CR-01 recommendedClinician Review CR-01
  4. Day 83 Patient acceptedStarted CR-01 in the companion
  5. Day 88 Deterioration detected before clinical escalationClinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 79.

Primary contributors, last 14 days
  • GI instability+24
  • Toxicity-9
  • Nutritional resilience-8
  • Inflammatory activity+4
  • Treatment adherence-3

What helped?

  • Clinician Review CR-01Day 82
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
63%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 65
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 58
    • WearableHRV 26 ms, trending down
  • Mucosal barrier integrity 60
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 72 and rising
    • WearableSleep 4.2 h, below personal baseline
  • Autonomic recovery 40
    • Wearable3,499 steps/day
    • WearableShort sleep window
  • Butyrate / short-chain fatty acid production 20
    • Daily logFibre intake low in recent food logs
  • Drug metabolism and exposure 20
    • BloodToxicity index 44
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.3 · butyrate capacity 48/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
29 ms
Sleep
5.5 h
Steps
3,616
Resting HR
69 bpm
Daily log: GI score 72, nutritional resilience 35, adherence 68.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0146947%S1958
P-0177847%S0859
P-0151444%S1163
P-0162343%S1652
P-0179543%S0661
P-0131042%S0157
P-0138841%S17CR-01improved59
P-0169741%S0955
P-0171541%S0556
P-0152140%S1453
P-0160640%S0659
P-0169940%S04GI-04improved69